(The following press release from Merck KGaA was received by e-mail. It was not confirmed by the sender.) News Release Your Contact Phyllis Carter +49 6151 72-7144 Merck: Detailed Results of Phase III Trial of L-BLP25 in Patients With Non-Small Cell Lung Cancer (START) to be Presented at ASCO • Confirmed: Primary endpoint of significantly improving overall survival not met • Predefined subgroup of patients receiving initial concurrent chemoradiotherapy: median overall survival of 30.8 months observed in patients treated with L-BLP25 compared to 20.6 months in patients receiving placebo (HR 0.78, p=0.016) in post hoc analysis • Detailed results to be presented on Tuesday, June 4 Darmstadt, May 16, 2013 – Merck announced today detailed results from the randomized Phase III START* trial of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). These results will be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago. The primary endpoint of improving overall survival (OS) was not met. In a predefined subgroup of patients receiving initial concurrent chemoradiotherapy (CRT), a combination of chemotherapy and radiotherapy given at the same time, a median overall survival of 30.8 months versus 20.6 months was observed based on a post hoc analysis in patients treated with L-BLP25 versus placebo respectively (HR 0.78, 95% CI 0.64–0.95, p=0.016, n=806). The results of the START trial will be presented during the Oral Abstract Session “Lung Cancer – Non-Small Cell Local-Regional / Small Cell / Other Thoracic Cancers” from 09.45 am to 12.45 pm on Tuesday, June 4. The complete news release can be downloaded at the following link: http://news.merck.de/N/0/D589CE5EF4A133A7C1257B6C0046F5EA/$File/Start_Asco_engli sch.pdf News releases from Merck KGaA, Darmstadt, Germany, are available at this address: www.merckgroup.com/media or for residents in the USA and Canada at www.emdgroup.com/media In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may change your subscription at any time by following either one of the following links: www.merckgroup.com/subscribe or www.emdgroup.com/subscribe And please feel free to unsubscribe this service with either www.merckgroup.com/subscribe or www.emdgroup.com/unsubscribe Thank you very much! Merck KGaA ,Darmstadt, Germany External Communications E-mail: Media.Relations@merck.de Hotline: +49 (0) 6151/72-5000 This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith. Click http://disclaimer.merck.de to access the German, French, Spanish and Portuguese versions of this disclaimer.
MERCK KGAA'S L-BLP25 TRIAL DID NOT MEET PRIMARY ENDPOINT (ENG)